CN114438782B - 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 - Google Patents
一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 Download PDFInfo
- Publication number
- CN114438782B CN114438782B CN202210296705.7A CN202210296705A CN114438782B CN 114438782 B CN114438782 B CN 114438782B CN 202210296705 A CN202210296705 A CN 202210296705A CN 114438782 B CN114438782 B CN 114438782B
- Authority
- CN
- China
- Prior art keywords
- fiber membrane
- polylactic acid
- iron
- cysteine
- composite fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 61
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229920000747 poly(lactic acid) Polymers 0.000 title claims abstract description 57
- 239000004626 polylactic acid Substances 0.000 title claims abstract description 57
- 239000002131 composite material Substances 0.000 title claims abstract description 48
- 239000012528 membrane Substances 0.000 title claims abstract description 47
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000001263 FEMA 3042 Substances 0.000 title claims abstract description 41
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 title claims abstract description 41
- 235000015523 tannic acid Nutrition 0.000 title claims abstract description 41
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 title claims abstract description 41
- 229940033123 tannic acid Drugs 0.000 title claims abstract description 41
- 229920002258 tannic acid Polymers 0.000 title claims abstract description 41
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 26
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 24
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000004819 osteoinduction Effects 0.000 title abstract description 5
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 230000002138 osteoinductive effect Effects 0.000 claims description 14
- 238000002791 soaking Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000010907 mechanical stirring Methods 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- 230000005686 electrostatic field Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000009987 spinning Methods 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 2
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 229910000883 Ti6Al4V Inorganic materials 0.000 claims 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 10
- 241000894006 Bacteria Species 0.000 abstract description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000758 substrate Substances 0.000 abstract description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- -1 iron ions Chemical class 0.000 abstract description 2
- 230000011164 ossification Effects 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 238000001338 self-assembly Methods 0.000 abstract description 2
- 238000006845 Michael addition reaction Methods 0.000 abstract 1
- 229920002253 Tannate Polymers 0.000 abstract 1
- 230000009920 chelation Effects 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 30
- 238000005457 optimization Methods 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 206010031252 Osteomyelitis Diseases 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000004349 growth plate Anatomy 0.000 description 3
- LTGQWIGRJSKNBP-UHFFFAOYSA-N hexahydrate;trihydrochloride Chemical compound O.O.O.O.O.O.Cl.Cl.Cl LTGQWIGRJSKNBP-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229910001447 ferric ion Inorganic materials 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229920002961 polybutylene succinate Polymers 0.000 description 2
- 239000004631 polybutylene succinate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/224—Esters of carboxylic acids; Esters of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
- D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/07—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with halogens; with halogen acids or salts thereof; with oxides or oxyacids of halogens or salts thereof
- D06M11/11—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with halogens; with halogen acids or salts thereof; with oxides or oxyacids of halogens or salts thereof with halogen acids or salts thereof
- D06M11/28—Halides of elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/325—Amines
- D06M13/342—Amino-carboxylic acids; Betaines; Aminosulfonic acids; Sulfo-betaines
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/32—Polyesters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,该方法首先采用静电纺丝技术制备了聚乳酸纤维基底,采用自组装法,将单宁酸三价铁离子鳌合,并将半胱氨酸通过迈克尔加成反应接枝在其表面,该方法综合了聚乳酸良好的生物相容性,单宁酸良好的抗氧化活性和对铁离子的螯合作用,铁具有广谱抗菌性及单宁酸‑铁配合物强化其对近红外光的响应等特性,该配合物在光热强效抗菌的同时,又可清除局部过量累积的活性氧,表现出抗氧化能力并刺激细胞增殖和促进成骨,作为骨修复材料具有良好的应用前景。
Description
技术领域
本发明属于医用高分子复合材料技术领域,特别是涉及一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法。
背景技术
全世界数百万患者患有骨疾病或骨缺损,骨修复材料的研发是亟需解决的难题,理想的人工骨合成生物材料应该具有良好的生物相容性、生物活性、骨诱导性和抗菌性。
聚乳酸(Polylactic acid,PLLA)由于其良好的生物相容性、可生物降解、无毒等优点,已经被美国食品药品监督管理局(FDA)批准用于临床应用,在临床上主要应用于引导骨组织再生、药物输送、软组织修复等,是目前人工骨生物医用材料的研究热点之一,但缺乏骨诱导和抗菌性能,这限制了它在骨组织工程中的应用。
单宁酸(Tannic acid,TA)是一种天然的抗氧化剂,具有一定的还原能力和抗菌性,而且能够响应近红外光。由于具有邻苯二酚的结构特点,TA被广泛用于基底表面修饰,用以改善材料与基底间的粘附性;此外TA具有抗氧化功能,当活性氧(ROS)的平衡因缺乏抗氧化剂或ROS产生系统的突变而被打破时,异常过量的ROS会通过损害蛋白质、脂质和DNA对人类造成病理上的有害影响。因此,清除过量ROS是十分必要的。据报道,氧化锰纳米颗粒、二氧化铈纳米颗粒、TA、没食子酸等都能有效地消除ROS,虽然几种金属氧化物表现出很强的ROS清除能力,但存在生物相容性差和潜在毒性等问题,TA这种天然的抗氧化剂就避免了这个问题,同时TA比其他天然抗氧化剂更稳定。因此,TA引入骨修复复合材料能赋予材料抗氧化性能。
骨感染是临床骨修复过程中急需攻克的难题,由于细菌所引起的骨感染会损害骨组织的愈合修复能力,导致植入物植入失败,因此研发具有抗菌性能的植入材料成为目前研究热点之一。骨感染主要由细菌感染引起,及时有效的杀死组织表面的细菌并抑制细菌生物膜的形成是抑制感染、促进骨组织愈合的关键所在。目前常见的治疗骨感染的方法是清创术和全身抗生素治疗,但在长期或过度使用抗生素会增加手术风险和产生耐药。因此,提高生物材料的细菌耐药性、抗骨感染能力成为亟待解决的难题。铁是人体必需的微量元素,三价铁离子(Ferric ion, Fe3+)具有广泛的抗菌性和抗细菌耐药性能,单宁酸与三价铁形成的配合物对近红外光具有响应性,在临床上被应用于杀灭生物材料上的细菌,其杀菌机制首先是Fe3+在细菌的细胞膜中积累和溶解,改变了细菌膜的通透性杀死细菌,其次水在TA-Fe配合物在近红外光的催化作用下产生了活性氧导致蛋白质功能障碍,从而杀死细菌,TA-Fe配合物对近红外光有响应,使得近红外光被吸收转化为热,进一步加强杀菌效果。因此将Fe3+纳米粒子引入骨修复复合材料能赋予材料快速、持久抗菌性能。
L-半胱氨酸(L-Cysteine,Cys),一种生物体内常见的氨基酸。Cys增加了 IGF-I的 mRNA 表达,生长板中的软骨内细胞增殖导致骨骼生长。Cys增加了生长板厚度(生长板厚度是线性骨生长的直接指标)。Cys通过 JAK2-STAT5 的磷酸化促进线性骨生长。Cys提高了胫骨骨密度(BMD)。Cys改善了骨骼参数(它增加了骨体积分数、骨小梁厚度、骨小梁数量、连接密度,并降低了总孔隙率)。同时,Cys中的巯基中含有的硫元素,对骨骼生长也具有促进作用。因此将Cys引入骨修复复合材料能赋予材料成骨性能。
静电纺丝技术可构建形貌可控、有类似于天然细胞外基质(Extracellularmatrix, ECM)的纤维结构,设计理想的仿生环境用于细胞粘附和增殖,促进新组织生长在骨组织工程中具有重要的应用价值。
基于此,综合PLLA良好的生物相容性和可降解性,TA对金属离子的高亲和力、还原能力和抗氧化性,三价铁离子的广谱抗菌性、抗细菌耐药性;TA-Fe配合物的光热效应;Cys的骨诱导性等各自特点,以及静电纺丝技术在构建形貌可控的仿生纤维结构方面的独特优势,本发明提供一种快速抗菌/抗氧化活性的PLLA/TA/Fe/Cys骨诱导复合纤维膜的制备方法。
发明内容
本发明的目的在于提供一种快速抗菌/抗氧化活性的PLLA/TA/Fe/Cys骨诱导复合纤维膜的制备方法,基于自组装技术将TA-Fe、Cys负载到生物相容性和可降解性优越的聚乳酸基纤维膜上,该骨修复材料能广泛应用于骨损伤修复和骨缺损治疗领域。
本发明通过下述的技术方案来实现:
一种快速抗菌/抗氧化活性的PLLA/TA/Fe/Cys骨诱导复合纤维膜的制备方法,包括如下步骤:
(1)将PLLA溶于有机溶剂中,机械搅拌使其完全溶解,得到均匀的聚乳酸静电纺丝溶液;
(2)以步骤(1)所得PLLA静电纺丝溶液为原料进行静电纺丝,得到PLLA纤维膜;
(3)将步骤(2)所得的PLLA纤维膜在真空条件下干燥完全后,将所得的纤维膜剪成一定尺寸的块状,保存在37℃的恒温箱中备用;
(4)将氯化钠溶于去离子水中,机械搅拌使其完全溶解;再加入TA,机械搅拌使其完全溶解;再加入三氯化铁(Ⅲ)六水合物,继续搅拌使溶解,并形成均一稳定的混合溶液。
(5)将步骤(3)所得的块状PLLA纤维膜浸泡于步骤(4)所得的混合溶液中,在常温下浸泡6h至反应完全,得到PLLA/TA/Fe复合纤维膜;
(6)将Cys溶于去离子水中,机械搅拌使其完全溶解;
(7)将步骤(5)所得的复合纤维膜浸泡于步骤(6)所得的Cys溶液中,在常温下浸泡12h至反应完全,得到PLLA/TA/Fe/Cys复合纤维膜;
(8)将步骤(7)所得的复合纤维膜在真空条件下干燥完全后,保存在37℃的恒温箱中备用。
作为本发明技术方案的进一步优化,步骤(1)中所述PLLA的加入浓度范围为100-220 g/L,步骤(4)中所述氯化钠的加入浓度范围为70 mM/L -80 Mm/L,单宁酸的加入浓度范围为0.5-2.0 g/L,三氯化铁(Ⅲ)六水合物的加入浓度范围为0-0.5 g/L,步骤(6)中所述半胱氨酸的加入浓度范围为0.5-1.0 g/L。
作为本发明技术方案的进一步优化,步骤(1)中所述的有机溶剂为三氟乙醇、六氟异丙醇、二氯甲烷、三氯甲烷、N, N-二甲基甲酰胺或二甲基亚砜中的至少一种。
作为本发明技术方案的进一步优化,步骤(1)、步骤(4)和步骤(6)中所述的机械搅拌转速范围为600-1600 r/min,其中步骤(1)的搅拌时间为10-24 h,步骤(4)和步骤(6)的搅拌时间为10-30min。
作为本发明技术方案的进一步优化,步骤(2)中所述的静电纺丝参数包括,高压静电场电压范围12-20 kV,纺丝接收间距10-20 cm,注射器推进速度2-4 mL/h,收集器的材质为钛、钛合金(Ti6Al4V)、铝或不锈钢。
作为本发明技术方案的进一步优化,步骤(4)中所述的三氯化铁(Ⅲ)六水合物为可溶于水铁盐的至少一种。
作为本发明技术方案的进一步优化,步骤(5)中所述的浸泡温度范围为室温,浸泡时间为6h;步骤(7)中所述的浸泡温度范围为室温,浸泡时间为12h。
作为本发明技术方案的进一步优化,步骤(3)和步骤(8)中所述的真空干燥温度为60-80℃,干燥时间为48-96 h。
作为本发明技术方案的进一步优化,所述铁为三价铁离子。
综上所述,本发明复合纤维膜的制备方法的优点在于:基于静电纺丝技术制备了一种快速抗菌/抗氧化活性的PLLA/TA/Fe/Cys骨诱导复合纤维膜,该复合纤维膜能模拟体内的天然细胞外基质,促进成骨和血管生成,达到快速并持久抗细菌感染,同时具有抗氧化的效果,从而促进骨组织修复。该制备方法操作简便,成本低廉,制得的复合纤维作为骨修复材料具有良好的应用前景。
附图说明
图1为本发明的实施例一制得的复合纤维膜的扫描电镜(SEM)图片;
图2为本发明的实施例一制得的复合纤维膜的能谱(EDS)图;
图3为本发明的实施例一制得的复合纤维膜接收近红外光照射以后温度随时间变化曲线图。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一
本发明提供一种快速抗菌/抗氧化活性的PLLA/TA/Fe/Cys骨诱导复合纤维膜的制备方法,包括如下步骤:
(1)将1.44 gPLLA溶于于9 ml三氟乙醇中,使用转速1300 r/min的机械搅拌16 h使其完全溶解,得到均匀的PLLA静电纺丝溶液;
(2)以步骤(1)所得PLLA静电纺丝溶液为原料进行静电纺丝,其参数为高压静电场电压15 kv,纺丝接收间距13 cm,注射器推进速度3 ml/h,得到附着于钛箔收集器表面的PLLA纤维膜;
(3)将步骤(2)所得的PLLA纤维膜在70℃下真空干燥72 h以完全除去残余溶剂,然后将所得的纤维膜剪成2 cm×2 cm的块状,保存在37℃的恒温箱中备用;
(4)将1.7532 g氯化钠溶于400 ml去离子水中,机械搅拌使其完全溶解;再加入0.8 gTA,使用转速1000 r/min的机械搅拌10min使其完全溶解;再加0.12 g入三氯化铁(Ⅲ)六水合物,使用转速1000 r/min的机械搅拌10min使其完全溶解,并形成均一稳定的混合溶液。
(5)将步骤(3)所得的块状PLLA纤维膜浸泡于步骤(4)所得的混合溶液中,在常温下浸泡6 h至反应完全,得到PLLA/TA/Fe复合纤维膜;
(6)将0.4g Cys溶于400 mL去离子水中,使用转速1000 r/min的机械搅拌10min使其完全溶解;
(7)将步骤(5)所得的复合纤维膜浸泡于步骤(6)所得的Cys溶液中,在常温下浸泡12h至反应完全,得到PLLA/TA/Fe/Cys复合纤维膜;
(8)将步骤(7)所得的复合纤维膜在真空条件下干燥完全后,保存在37℃的恒温箱中备用。
如图1-3所示,图1为PLLA/TA/Fe/Cys复合纤维的SEM图,从图中可以看出,复合纤维上的Fe3+分布较为均匀,尺寸较小,其抗菌性会越好;图2为PLLA/TA/Fe/Cys复合纤维的EDS图,从图中可以看出,复合纤维上的铁元素分布较为均匀;图3为接收近红外光照射以后温度随时间变化曲线图,从图中可以看出,当复合纤维接受功率为1.5W、频率为808 nm的近红外光照射10min时,PLLA/TA复合纤维比聚丁二酸丁二醇酯(PBS)和PLLA纤维在相同时间时具有较高的温度,说明TA对近红外光具有一定的响应性,但光产生热的效果不佳,而PLLA/TA/Fe/Cys复合纤维的温度达到了55.3℃,接近杀死细菌的温度且在人体组织可承受的温度范围内,说明TA-Fe吸收了近红外光后将光转化为了热,结合铁的物理杀菌作用,会使得铁在更短的时间内快速杀死细菌。
以上所述,仅用以说明本发明的技术方案而非限制,本领域普通技术人员对本发明的技术方案所做的其它修改或者等同替换,只要不脱离本发明技术方案的精神和范围,均应涵盖在本发明的权利要求范围当中。
Claims (8)
1.一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于,包括如下步骤:
(1)将聚乳酸溶于有机溶剂中,机械搅拌使其完全溶解,得到均匀的聚乳酸静电纺丝溶液;
(2)以步骤(1)所得聚乳酸静电纺丝溶液为原料进行静电纺丝,得到聚乳酸纤维膜;
(3)将步骤(2)所得的聚乳酸纤维膜在真空条件下干燥完全后,将所得的纤维膜剪成一定尺寸的块状,保存在37℃的恒温箱中备用;
(4)将氯化钠溶于去离子水中,机械搅拌使其完全溶解;再加入TA,机械搅拌使其完全溶解;再加入三氯化铁六水合物,继续搅拌使溶解,并形成均一稳定的混合溶液;
(5)将步骤(3)所得的块状聚乳酸纤维膜浸泡于步骤(4)所得的混合溶液中,在常温下浸泡至反应完全,得到聚乳酸/单宁酸/铁复合纤维膜;
(6)将半胱氨酸溶于去离子水中,机械搅拌使其完全溶解;
(7)将步骤(5)所得的复合纤维膜浸泡于步骤(6)所得的半胱氨酸溶液中,在常温下浸泡至反应完全,得到聚乳酸/单宁酸/铁/半胱氨酸复合纤维膜;
(8)将步骤(7)所得的复合纤维膜在真空条件下干燥完全后,保存在37℃的恒温箱中备用。
2.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(1)中所述聚乳酸的加入浓度范围为100-220g/L,步骤(4)中所述氯化钠的加入浓度范围为70mM/L-80mM/L,TA的加入浓度范围为0.5-2.0g/L,三氯化铁六水合物的加入浓度范围为0-0.5g/L,浓度不为0,步骤(6)中所述半胱氨酸的加入浓度范围为0.5-1.0g/L。
3.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(1)中所述的有机溶剂为三氟乙醇、六氟异丙醇、二氯甲烷、三氯甲烷、N,N-二甲基甲酰胺或二甲基亚砜中的至少一种。
4.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(1)、步骤(4)和步骤(6)中所述的机械搅拌转速范围为600-1600r/min,其中步骤(1)的搅拌时间为10-24h,步骤(4)和步骤(6)的搅拌时间为10-30min。
5.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(2)中所述的静电纺丝参数包括,高压静电场电压范围12-20kV,纺丝接收间距10-20cm,注射器推进速度2-4mL/h,收集器的材质为钛、钛合金Ti6Al4V、铝或不锈钢。
6.根据权利要求1或2所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(4)中所述的三氯化铁六水合物为可溶于水铁盐的至少一种。
7.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(5)中所述的浸泡温度范围为室温,浸泡时间至少为6h;步骤(7)中所述的浸泡温度范围为室温,浸泡时间至少为12h。
8.根据权利要求1所述的一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法,其特征在于:步骤(3)和步骤(8)中所述的真空干燥温度为60-80℃,干燥时间为48-96h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210296705.7A CN114438782B (zh) | 2022-03-24 | 2022-03-24 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210296705.7A CN114438782B (zh) | 2022-03-24 | 2022-03-24 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114438782A CN114438782A (zh) | 2022-05-06 |
CN114438782B true CN114438782B (zh) | 2023-05-02 |
Family
ID=81359404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210296705.7A Active CN114438782B (zh) | 2022-03-24 | 2022-03-24 | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114438782B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115054741A (zh) * | 2022-06-28 | 2022-09-16 | 成都世联康健生物科技有限公司 | 防粘连膜、制法及金属-酚复合物在制备防粘连膜中的应用 |
CN116212100A (zh) * | 2023-01-10 | 2023-06-06 | 华中科技大学同济医学院附属协和医院 | 用于治疗口腔创面的自修复抗氧化水凝胶敷料及制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106319757A (zh) * | 2016-11-15 | 2017-01-11 | 天津捷盛东辉保鲜科技有限公司 | 电纺聚乙烯醇基单宁酸抗氧化纳米纤维膜 |
CN112402699A (zh) * | 2020-12-09 | 2021-02-26 | 新疆师范大学 | 一种具有骨诱导和抗菌功能的聚乳酸/地塞米松/纳米金属复合纤维膜的制备方法 |
CN112575576A (zh) * | 2021-01-15 | 2021-03-30 | 新疆师范大学 | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 |
CN113769166A (zh) * | 2021-09-26 | 2021-12-10 | 四川大学华西医院 | 包含金属-多酚网络的骨修复材料及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100875189B1 (ko) * | 2005-08-26 | 2008-12-19 | 이화여자대학교 산학협력단 | 전기방사를 이용한 조직 재생용 섬유형 삼차원 다공성 지지체 및 그의 제조방법 |
PL3072536T3 (pl) * | 2013-11-19 | 2020-12-28 | Shanghai P & P Biotech Co., Ltd | Hydrofilowy elektroprzędzony kompozytowy biologiczny materiał stentowy stosowany do regeneracji i otrzymywania tkanki i jego zastosowanie |
CN111035804A (zh) * | 2019-12-16 | 2020-04-21 | 深圳市光远生物材料有限责任公司 | 一种软组织修复纤维膜材料及其制备方法和应用 |
-
2022
- 2022-03-24 CN CN202210296705.7A patent/CN114438782B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106319757A (zh) * | 2016-11-15 | 2017-01-11 | 天津捷盛东辉保鲜科技有限公司 | 电纺聚乙烯醇基单宁酸抗氧化纳米纤维膜 |
CN112402699A (zh) * | 2020-12-09 | 2021-02-26 | 新疆师范大学 | 一种具有骨诱导和抗菌功能的聚乳酸/地塞米松/纳米金属复合纤维膜的制备方法 |
CN112575576A (zh) * | 2021-01-15 | 2021-03-30 | 新疆师范大学 | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 |
CN113769166A (zh) * | 2021-09-26 | 2021-12-10 | 四川大学华西医院 | 包含金属-多酚网络的骨修复材料及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN114438782A (zh) | 2022-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112575576B (zh) | 一种具有光热/铜协同抗菌功能的聚多巴胺/聚乳酸/纳米铜复合纤维膜的制备方法 | |
Islam et al. | Chitosan based bioactive materials in tissue engineering applications-A review | |
CN114438782B (zh) | 一种快速抗菌/抗氧化活性的聚乳酸/单宁酸/铁/半胱氨酸骨诱导复合纤维膜的制备方法 | |
Brennan et al. | Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix | |
Chen et al. | Silk fibroin combined with electrospinning as a promising strategy for tissue regeneration | |
De Olyveira et al. | First otoliths/collagen/bacterial cellulose nanocomposites as a potential scaffold for bone tissue regeneration | |
CN107213529B (zh) | 一种用于提高成骨细胞粘附和成骨性能的可降解医用高分子三维材料的制备方法 | |
Cao et al. | Porous ZnO modified silk sutures with dual light defined antibacterial, healing promotion and controlled self-degradation capabilities | |
CN106215239B (zh) | 一种交联抗菌型脱细胞基质材料的制备方法 | |
Zhang et al. | Biodegradable hydrogels with photodynamic antibacterial activity promote wound healing and mitigate scar formation | |
Wu et al. | Electrospun fibers immobilized with BMP-2 mediated by polydopamine combined with autogenous tendon to repair developmental dysplasia of the hip in a porcine model | |
Xu et al. | Copper Ion‐Modified germanium phosphorus nanosheets integrated with an electroactive and biodegradable hydrogel for Neuro‐Vascularized bone regeneration | |
Zhou et al. | Surface configuration of microarc oxidized Ti with regionally loaded chitosan hydrogel containing ciprofloxacin for improving biological performance | |
Dong et al. | Polymer scaffolds-enhanced bone regeneration in osteonecrosis therapy | |
Zhao et al. | 3D Printed Photothermal Scaffold Sandwiching Bacteria Inside and Outside Improves The Infected Microenvironment and Repairs Bone Defects | |
Sun et al. | Highly active biological dermal acellular tissue scaffold composite with human bone powder for bone regeneration | |
CN117339008A (zh) | 用于治疗感染性骨缺损3d打印pekk负载异制结体系 | |
Scomazzon et al. | An increase in Wharton's jelly membrane osteocompatibility by a genipin-cross-link | |
Sivashankari et al. | Bioactive nanomaterials/chitosan composites as scaffolds for tissue regeneration | |
CN114288473A (zh) | 一种具有抑菌功能的脱细胞小肠粘膜下层复合骨支架的制备方法 | |
CN112999430B (zh) | 口腔修复膜及其制备方法 | |
CN115068678A (zh) | 一种HAase/NIR响应性钛植入体及其制备方法和应用 | |
Naghibzadeh | Nanofibers for Skin Regeneration. | |
Moradi et al. | A novel composite nano-scaffold with potential usage as skin dermo-epidermal grafts for chronic wound treatment | |
CN106618765A (zh) | 一种用于牙科种植体的抗菌肽层 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |